EARS unveils AM-111 Phase 3 trial outcomes in a peer-reviewed article
Category: #health  By Paroma Bhattacharya  Date: 2019-03-12
  • share
  • Twitter
  • Facebook
  • LinkedIn

EARS unveils AM-111 Phase 3 trial outcomes in a peer-reviewed article

Auris Medical Holding AG (EARS), a Switzerland-headquartered pharmaceutical company, has reportedly announced the publication of a peer-reviewed scientific article which contains detailed outcomes of the HEALOS Phase 3 trial with AM-111. AM-111 for the record, is the investigational treatment developed by Auris Medical for severe inner ear hearing loss.

Reportedly, the article that discusses the efficacy & safety of AM-111 in the treatment of unilateral sudden deafness in randomized, placebo-controlled Phase 3 study, has been published in one of the leading scientific journals in the field of clinical inner ear research, named Otology & Neurotology.

Hinrich Staecker, PhD, MD, University of Kansas Medical Center, who is also the lead author of the book, was quoted stating that the HEALOS trial shows that the right hearing protection can be possible through a drug-based approach, even in case of acute hearing loss, with poor prognosis for recovery and high risk of cognitive disability. He went on to say that treating with a single dose of AM-111 led to a clinically profound hearing recovery in the trial and marked the signs of improvement and moreover, he affirmed that the outcomes appear to be quite promising.

According to a press release by Auris Medical, the HEALOS trial was conducted in several Asian and European countries and enrolled around 256 patients victimized by severe, sudden deafness. The patients were reportedly randomized in a 1:1:1 ratio for receiving a single dose of AM-111 0.8 mg/mL, AM-111 0.4 mg/mL or placebo, to be administered in the middle ear. However, the trial did not meet the prime efficacy endpoint in the entire study population but, the post-hoc analyses showed significant improvement with AM-111, right from the baseline to Day 28.

For those uninitiated, AM-111 is developed with a biocompatible gel formulation for treating sudden sensorineural hearing loss. It holds an orphan drug designation (ODD) from both the European Medicines Agency (EMA) and US FDA (Food & Drug Administration) and was granted a Fast Track status by the FDA.



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

FamilyMart to end Chinese joint venture partnership with Ting Hsin
FamilyMart to end Chinese joint venture partnership with Ting Hsin
By Paroma Bhattacharya

Ting Hsin operates overs 2,500 FamilyMart stores in China, sharing revenues and paying royalties to the Japanese firm.

Japan-based convenience store operator, Famil...

FDA and IBT seemingly in agreement on Phase III study design
FDA and IBT seemingly in agreement on Phase III study design
By Paroma Bhattacharya

The US Food and Drug Administration (FDA) has reportedly informed Infant Bacterial Therapeutics (IBT) in writing that the company has responded reasonably to its comments pertaining to the Phase III study design and th...

Kohl’s expresses interest in the acquisition of At Home décor chain
Kohl’s expresses interest in the acquisition of At Home décor chain
By Paroma Bhattacharya

At Home has been exploring a sale, for the last 3 months and has already advanced in a deal negotiation with private equity firms, including Hellman and Friedman.

The largest U.S. department store chain operator Kohl&rsquo...